Skip to main content

Articles

Page 22 of 38

  1. Even though hematopoietic stem cell transplantation can be curative in patients with severe combined immunodeficiency, there is a need for additional strategies boosting T cell immunity in individuals sufferin...

    Authors: Andrea Z. Tuckett, Raymond H. Thornton, Richard J. O’Reilly, Marcel R. M. van den Brink and Johannes L. Zakrzewski
    Citation: Journal of Hematology & Oncology 2017 10:109
  2. In our previous SMC NB-2004 study of patients with high-risk neuroblastomas, which incorporated total-body irradiation (TBI) with second high-dose chemotherapy and autologous stem cell transplantation (HDCT/au...

    Authors: Ji Won Lee, Sanghoon Lee, Hee Won Cho, Youngeun Ma, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Eun Joo Cho, Suk-Koo Lee and Do Hoon Lim
    Citation: Journal of Hematology & Oncology 2017 10:108
  3. A microRNA (miRNA) collection on the imprinted 14q32 MEG3 region has been associated with outcome in osteosarcoma. We assessed the clinical utility of this miRNA set and their association with methylation status.

    Authors: Katherine E. Hill, Andrew D. Kelly, Marieke L. Kuijjer, William Barry, Ahmed Rattani, Cassandra C. Garbutt, Haydn Kissick, Katherine Janeway, Antonio Perez-Atayde, Jeffrey Goldsmith, Mark C. Gebhardt, Mohamed S. Arredouani, Greg Cote, Francis Hornicek, Edwin Choy, Zhenfeng Duan…
    Citation: Journal of Hematology & Oncology 2017 10:107
  4. Cancers remain a major public health problem worldwide, which still require profound research in both the basic and preclinical fields. Patient-derived xenograft (PDX) models are created when cancerous cells o...

    Authors: Yunxin Lai, Xinru Wei, Shouheng Lin, Le Qin, Lin Cheng and Peng Li
    Citation: Journal of Hematology & Oncology 2017 10:106
  5. Studies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis.

    Authors: Mei-feng Li, Xiao-li Li, Kai-liang Fan, Ying-yi Yu, Jing Gong, Shu-ying Geng, Ya-feng Liang, Ling Huang, Ji-hua Qiu, Xing-han Tian, Wen-ting Wang, Xiao-lu Zhang, Qing-xia Yu, Yuan-feng Zhang, Peng Lin, Li-na Wang…
    Citation: Journal of Hematology & Oncology 2017 10:104
  6. Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to escape immune surveillance. Accumulating data suppor...

    Authors: Chi Young Ok and Ken H. Young
    Citation: Journal of Hematology & Oncology 2017 10:103
  7. Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threat...

    Authors: Chongsheng Qian, Arnaud Campidelli, Yingying Wang, Huili Cai, Véronique Venard, Hélène Jeulin, Jean Hugues Dalle, Cécile Pochon, Maud D’aveni, Benedicte Bruno, Catherine Paillard, Stéphane Vigouroux, Charlotte Jubert, Patrice Ceballos, Aude Marie-Cardine, Claire Galambrun…
    Citation: Journal of Hematology & Oncology 2017 10:102
  8. Wnt/β-catenin signaling, a highly conserved pathway through evolution, regulates key cellular functions including proliferation, differentiation, migration, genetic stability, apoptosis, and stem cell renewal....

    Authors: Sachin Gopalkrishna Pai, Benedito A. Carneiro, Jose Mauricio Mota, Ricardo Costa, Caio Abner Leite, Romualdo Barroso-Sousa, Jason Benjamin Kaplan, Young Kwang Chae and Francis Joseph Giles
    Citation: Journal of Hematology & Oncology 2017 10:101
  9. Solid tumors residing in tissues and organs leave footprints in circulation through circulating tumor cells (CTCs) and circulating tumor DNAs (ctDNA). Characterization of the ctDNA portraits and comparison wit...

    Authors: Meng Yang, Umit Topaloglu, W. Jeffrey Petty, Matthew Pagni, Kristie L. Foley, Stefan C. Grant, Mac Robinson, Rhonda L. Bitting, Alexandra Thomas, Angela T. Alistar, Rodwige J. Desnoyers, Michael Goodman, Carol Albright, Mercedes Porosnicu, Mihaela Vatca, Shadi A. Qasem…
    Citation: Journal of Hematology & Oncology 2017 10:100
  10. We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia

    Authors: Bing Li, Robert Peter Gale, Zefeng Xu, Tiejun Qin, Zhen Song, Peihong Zhang, Jie Bai, Lei Zhang, Yue Zhang, Jinqin Liu, Gang Huang and Zhijian Xiao
    Citation: Journal of Hematology & Oncology 2017 10:99
  11. HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall sur...

    Authors: Xichun Hu, Wei Huang and Minhao Fan
    Citation: Journal of Hematology & Oncology 2017 10:98
  12. Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which ar...

    Authors: Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell and Kongming Wu
    Citation: Journal of Hematology & Oncology 2017 10:97
  13. Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies...

    Authors: Kathan Mehta, Keyur Patel and Rahul A. Parikh
    Citation: Journal of Hematology & Oncology 2017 10:95
  14. Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully ov...

    Authors: Tala Achkar and Ahmad A. Tarhini
    Citation: Journal of Hematology & Oncology 2017 10:88
  15. Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and tumor recurrence and metastasis are major factors that contribute to the poor outcome of patients with HCC. Long noncoding R...

    Authors: Wen Ni, Yuqin Zhang, Zetao Zhan, Feng Ye, Yonghao Liang, Jing Huang, Keli Chen, Longhua Chen and Yi Ding
    Citation: Journal of Hematology & Oncology 2017 10:91

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:51

  16. Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely ...

    Authors: Caner Saygin and Hetty E. Carraway
    Citation: Journal of Hematology & Oncology 2017 10:93
  17. The B cell maturation process involves multiple steps, which are controlled by relevant pathways and transcription factors. The understanding of the final stages of plasma cell (PC) differentiation could provi...

    Authors: Dalia Quwaider, Luis A. Corchete, Irena Misiewicz-Krzeminska, María E. Sarasquete, José J. Pérez, Patryk Krzeminski, Noemí Puig, María Victoria Mateos, Ramón García-Sanz, Ana B. Herrero and Norma C. Gutiérrez
    Citation: Journal of Hematology & Oncology 2017 10:92
  18. The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjögren syndrome (SjS).

    Authors: Pilar Brito-Zerón, Belchin Kostov, Guadalupe Fraile, Daniel Caravia-Durán, Brenda Maure, Francisco-Javier Rascón, Mónica Zamora, Arnau Casanovas, Miguel Lopez-Dupla, Mar Ripoll, Blanca Pinilla, Eva Fonseca, Miriam Akasbi, Gloria de la Red, Miguel-Angel Duarte-Millán, Patricia Fanlo…
    Citation: Journal of Hematology & Oncology 2017 10:90
  19. Estrogen and progesterone are potent breast mitogens. In addition to steroid hormones, multiple signaling pathways input to estrogen receptor (ER) and progesterone receptor (PR) actions via posttranslational e...

    Authors: Todd P. Knutson, Thu H. Truong, Shihong Ma, Nicholas J. Brady, Megan E. Sullivan, Ganesh Raj, Kathryn L. Schwertfeger and Carol A. Lange
    Citation: Journal of Hematology & Oncology 2017 10:89
  20. Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignancy of putative NK-cell origin, with a minority deriving from the T-cell lineage. Pathologically, the malignancy occurs in two forms, extr...

    Authors: Eric Tse and Yok-Lam Kwong
    Citation: Journal of Hematology & Oncology 2017 10:85
  21. Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of...

    Authors: Audrey Laroche, Vanessa Chaire, François Le Loarer, Marie-Paule Algéo, Christophe Rey, Kevin Tran, Carlo Lucchesi and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2017 10:84
  22. Chronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic...

    Authors: Miguel Quijada-Álamo, María Hernández-Sánchez, Cristina Robledo, Jesús-María Hernández-Sánchez, Rocío Benito, Adrián Montaño, Ana E. Rodríguez-Vicente, Dalia Quwaider, Ana-África Martín, María García-Álvarez, María Jesús Vidal-Manceñido, Gonzalo Ferrer-Garrido, María-Pilar Delgado-Beltrán, Josefina Galende, Juan-Nicolás Rodríguez, Guillermo Martín-Núñez…
    Citation: Journal of Hematology & Oncology 2017 10:83
  23. Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus, we posit that DC-based immunotherapy, in conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is...

    Authors: Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett-Mayer, Colleen A. Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres M. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li and David J. Cole
    Citation: Journal of Hematology & Oncology 2017 10:82
  24. Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Br...

    Authors: P. Balsas, A. Esteve-Arenys, J. Roldán, L. Jiménez, V. Rodríguez, J. G. Valero, A. Chamorro-Jorganes, R. Puig de la Bellacasa, J. Teixidó, A. Matas-Céspedes, A. Moros, A. Martínez, E. Campo, A. Sáez-Borderías, J. I. Borrell, P. Pérez-Galán…
    Citation: Journal of Hematology & Oncology 2017 10:80
  25. With persistent inconsistencies in colorectal cancer (CRC) miRNAs expression data, it is crucial to shift toward inclusion of a “pre-laboratory” integrated analysis to expedite effective precision medicine and...

    Authors: Min Sun, Haibin Song, Shuyi Wang, Chunxiao Zhang, Liang Zheng, Fangfang Chen, Dongdong Shi, Yuanyuan Chen, Chaogang Yang, Zhenxian Xiang, Qing Liu, Chen Wei and Bin Xiong
    Citation: Journal of Hematology & Oncology 2017 10:79
  26. The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tu...

    Authors: Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han and Kongming Wu
    Citation: Journal of Hematology & Oncology 2017 10:78
  27. The inhibition of the DNA damage response (DDR) pathway in the treatment of cancers has recently reached an exciting stage with several cell cycle checkpoint inhibitors that are now being tested in several cli...

    Authors: A. Ghelli Luserna di Rora’, I. Iacobucci and G. Martinelli
    Citation: Journal of Hematology & Oncology 2017 10:77
  28. Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of the desmoplastic stroma characteristi...

    Authors: Dagny von Ahrens, Tushar D. Bhagat, Deepak Nagrath, Anirban Maitra and Amit Verma
    Citation: Journal of Hematology & Oncology 2017 10:76
  29. ELF2 (E74-like factor 2) also known as NERF (new Ets-related factor), a member of the Ets family of transcription factors, regulates genes important in B and T cell development, cell cycle progression, and angiog...

    Authors: Fiona H. X. Guan, Charles G. Bailey, Cynthia Metierre, Patrick O’Young, Dadi Gao, Teh Liane Khoo, Jeff Holst and John E. J. Rasko
    Citation: Journal of Hematology & Oncology 2017 10:75
  30. Current angiogenic therapies for cancers and cardiovascular diseases have not yet achieved expected benefits, which reflects the need for improved understanding of angiogenesis. In this study, we focused on so...

    Authors: Hangfei Fu, Nish Vadalia, Eric R. Xue, Candice Johnson, Luqiao Wang, William Y. Yang, Claudette Sanchez, Jun Nelson, Qian Chen, Eric T. Choi, Jian-Xing Ma, Jun Yu, Hong Wang and Xiaofeng Yang
    Citation: Journal of Hematology & Oncology 2017 10:74
  31. Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow t...

    Authors: Saroj Vadhan-Raj, Rafat Abonour, Jonathan W. Goldman, David A. Smith, Christopher A. Slapak, Robert L. Ilaria Jr, Ramon V. Tiu, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, Yiu-Keung Lau and Eric J. Roeland
    Citation: Journal of Hematology & Oncology 2017 10:73
  32. Polymeric fibronectin (polyFN) assembled on suspended breast cancer cells is required for metastasis. Conceivably, drugs that target such polyFN may fight against cancer metastasis. While stilbene analogs trig...

    Authors: Ying-Jan Wang, Jing-Fang Lin, Li-Hsin Cheng, Wen-Tsan Chang, Ying-Hsien Kao, Ming-Min Chang, Bour-Jr Wang and Hung-Chi Cheng
    Citation: Journal of Hematology & Oncology 2017 10:72
  33. Melittin is the main effective component of bee venom and has extensive biological functions; however, serious side effects have restricted its clinical application. Preclinical and clinical studies showed tha...

    Authors: Jie Mao, Shujun Liu, Min Ai, Zhuo Wang, Duowei Wang, Xianjing Li, Kaiyong Hu, Xinghua Gao and Yong Yang
    Citation: Journal of Hematology & Oncology 2017 10:71

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:130

  34. Recently, the mutational background of diffuse large B cell lymphoma (DLBCL) has been revealed, identifying specific genetic events that drive lymphomagenesis. However, the prognostic value of these mutations ...

    Authors: Darius Juskevicius, David Jucker, Dirk Klingbiel, Christoph Mamot, Stephan Dirnhofer and Alexandar Tzankov
    Citation: Journal of Hematology & Oncology 2017 10:70
  35. The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Foo...

    Authors: Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Zhengming Jin, Zhiming Li, Lugui Qiu, Mei Dong…
    Citation: Journal of Hematology & Oncology 2017 10:69
  36. Multiple iterations of chimeric antigen receptors (CARs) have been developed, mainly focusing on intracellular signaling modules. However, the effect of non-signaling extracellular modules on the expansion and...

    Authors: Le Qin, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, Yangqiu Li, Xuchao Zhang, Yilong Wu, Pentao Liu, Yao Yao…
    Citation: Journal of Hematology & Oncology 2017 10:68
  37. In the last decade, the role for noncoding RNAs in disease was clearly established, starting with microRNAs and later expanded towards long noncoding RNAs. This was also the case for T cell acute lymphoblastic...

    Authors: Annelynn Wallaert, Kaat Durinck, Tom Taghon, Pieter Van Vlierberghe and Frank Speleman
    Citation: Journal of Hematology & Oncology 2017 10:66
  38. Relapsed acute lymphoblastic leukemia (ALL) is the leading cause of deaths of childhood cancer. Although relapse usually happens in the bone marrow, extramedullary relapse occasionally occurs including either ...

    Authors: Ling-Wen Ding, Qiao-Yang Sun, Anand Mayakonda, Kar-Tong Tan, Wenwen Chien, De-Chen Lin, Yan-Yi Jiang, Liang Xu, Manoj Garg, Zhen-Tang Lao, Michael Lill, Henry Yang, Allen Eng Juh Yeoh and H. Phillip Koeffler
    Citation: Journal of Hematology & Oncology 2017 10:65
  39. Adoptive transfer of cytotoxic T lymphocytes (CTLs) holds promises to cure cancer. However, this treatment is hindered by lacking a robust way to specifically expand out CTLs. Here, we developed a hybrid of B ...

    Authors: Sheng Chen, Feifei Gu, Kang Li, Kai Zhang, Yangyang Liu, Jinyan Liang, Wei Gao, Gang Wu and Li Liu
    Citation: Journal of Hematology & Oncology 2017 10:63
  40. Cancer has been a major public health problem that has threatened human life worldwide throughout history. The main causes that contribute to the poor prognosis of cancer are metastasis and recurrence. Cancer ...

    Authors: Xiaoxing Huang, Ruijing Xiao, Shan Pan, Xiangyong Yang, Wen Yuan, Zhenbo Tu, Ming Xu, Yufan Zhu, Qian Yin, Yingjie Wu, Weidong Hu, Liang Shao, Jie Xiong and Qiuping Zhang
    Citation: Journal of Hematology & Oncology 2017 10:62
  41. Target-specific next-generation sequencing technology was used to analyze 112 genes in adult patients with acute lymphoblastic leukemia (ALL). This sequencing mainly focused on the specific mutational hotspots...

    Authors: Juan Feng, Yan Li, Yujiao Jia, Qiuyun Fang, Xiaoyuan Gong, Xiaobao Dong, Kun Ru, Qinghua Li, Xingli Zhao, Kaiqi Liu, Min Wang, Zheng Tian, Yannan Jia, Ying Wang, Dong Lin, Hui Wei…
    Citation: Journal of Hematology & Oncology 2017 10:61
  42. An increased expression of Yes-associated protein (YAP1) has been shown to promote tumorigenesis in many cancer types including colon. However, the role of YAP1 in promoting colon tumorigenesis remains unclear...

    Authors: Yan-Jiun Huang, Ching-Kuo Yang, Po-Li Wei, Thanh-Tuan Huynh, Jacqueline Whang-Peng, Tzu-Ching Meng, Michael Hsiao, Yew-Ming Tzeng, Alexander TH Wu and Yun Yen
    Citation: Journal of Hematology & Oncology 2017 10:60

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here